Insider Selling: Lantheus Holdings, Inc. (NASDAQ:LNTH) CAO Sells 341 Shares of Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH) CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction on Monday, April 15th. The stock was sold at an average price of $61.24, for a total transaction of $20,882.84. Following the sale, the chief accounting officer now owns 63,239 shares of the company’s stock, valued at $3,872,756.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Andrea Sabens also recently made the following trade(s):

• On Tuesday, February 13th, Andrea Sabens sold 341 shares of Lantheus stock. The stock was sold at an average price of $55.31, for a total value of $18,860.71.

Lantheus Trading Up 1.4 %

Lantheus stock opened at $62.33 on Friday. The firm has a market cap of $4.27 billion, a PE ratio of 13.43 and a beta of 0.53. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $100.85. The stock’s 50 day simple moving average is $60.66 and its two-hundred day simple moving average is $62.99. The company has a current ratio of 5.80, a quick ratio of 5.45 and a debt-to-equity ratio of 0.69.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. The firm had revenue of $354.00 million for the quarter, compared to the consensus estimate of $350.44 million. Analysts anticipate that Lantheus Holdings, Inc. will post 5.72 earnings per share for the current year.

Analysts Set New Price Targets

LNTH has been the topic of a number of research reports. JMP Securities reissued a “market outperform” rating and issued a $100.00 price objective on shares of Lantheus in a report on Friday, February 23rd. Truist Financial reiterated a “buy” rating and issued a $82.00 price target (up previously from $80.00) on shares of Lantheus in a report on Monday, February 26th. B. Riley lifted their price objective on shares of Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research note on Thursday. Finally, StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $104.71.

Institutional Investors Weigh In On Lantheus

A number of institutional investors have recently modified their holdings of LNTH. Tucker Asset Management LLC raised its holdings in Lantheus by 239.0% in the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 282 shares during the period. Parkside Financial Bank & Trust raised its stake in shares of Lantheus by 60.2% during the 2nd quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 160 shares during the period. First Horizon Advisors Inc. lifted its position in shares of Lantheus by 97.0% during the 3rd quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 225 shares in the last quarter. Principal Securities Inc. acquired a new stake in Lantheus in the 4th quarter valued at $28,000. Finally, West Tower Group LLC increased its holdings in Lantheus by 534.1% in the 4th quarter. West Tower Group LLC now owns 520 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 438 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.